GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Cyclically Adjusted Revenue per Share

Exact Sciences (STU:EXK) Cyclically Adjusted Revenue per Share : €6.68 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Exact Sciences's adjusted revenue per share for the three months ended in Mar. 2024 was €3.216. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.68 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Exact Sciences's average Cyclically Adjusted Revenue Growth Rate was 28.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 39.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 52.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 60.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Exact Sciences was 91.70% per year. The lowest was -5.40% per year. And the median was 51.30% per year.

As of today (2024-06-09), Exact Sciences's current stock price is €40.64. Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €6.68. Exact Sciences's Cyclically Adjusted PS Ratio of today is 6.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Exact Sciences was 273.00. The lowest was 5.72. And the median was 70.96.


Exact Sciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted Revenue per Share Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 2.11 3.16 4.97 6.45

Exact Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.35 5.75 6.36 6.45 6.68

Competitive Comparison of Exact Sciences's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted PS Ratio falls into.



Exact Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exact Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.216/131.7762*131.7762
=3.216

Current CPI (Mar. 2024) = 131.7762.

Exact Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.014 99.070 0.019
201503 0.044 99.621 0.058
201506 0.081 100.684 0.106
201509 0.119 100.392 0.156
201512 0.137 99.792 0.181
201603 0.137 100.470 0.180
201606 0.193 101.688 0.250
201609 0.239 101.861 0.309
201612 0.306 101.863 0.396
201703 0.409 102.862 0.524
201706 0.455 103.349 0.580
201709 0.511 104.136 0.647
201712 0.615 104.011 0.779
201803 0.605 105.290 0.757
201806 0.721 106.317 0.894
201809 0.826 106.507 1.022
201812 1.022 105.998 1.271
201903 1.136 107.251 1.396
201906 1.369 108.070 1.669
201909 1.533 108.329 1.865
201912 1.900 108.420 2.309
202003 2.125 108.902 2.571
202006 1.595 108.767 1.932
202009 2.309 109.815 2.771
202012 2.449 109.897 2.937
202103 1.993 111.754 2.350
202106 2.104 114.631 2.419
202109 2.256 115.734 2.569
202112 2.431 117.630 2.723
202203 2.533 121.301 2.752
202206 2.798 125.017 2.949
202209 2.985 125.227 3.141
202212 2.939 125.222 3.093
202303 3.151 127.348 3.261
202306 3.186 128.729 3.261
202309 3.198 129.860 3.245
202312 3.275 129.419 3.335
202403 3.216 131.776 3.216

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Exact Sciences  (STU:EXK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exact Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=40.64/6.68
=6.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Exact Sciences was 273.00. The lowest was 5.72. And the median was 70.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Exact Sciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (STU:EXK) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.